A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model

Cerebellum. 2024 Feb;23(1):181-196. doi: 10.1007/s12311-023-01524-6. Epub 2023 Feb 2.

Abstract

Modeling paraneoplastic neurological diseases to understand the immune mechanisms leading to neuronal death is a major challenge given the rarity and terminal access of patients' autopsies. Here, we present a pilot study aiming at modeling paraneoplastic cerebellar degeneration with Yo autoantibodies (Yo-PCD). Female mice were implanted with an ovarian carcinoma cell line expressing CDR2 and CDR2L, the known antigens recognized by anti-Yo antibodies. To boost the immune response, we also immunized the mice by injecting antigens with diverse adjuvants and immune checkpoint inhibitors. Ataxia and gait instability were assessed in treated mice as well as autoantibody levels, Purkinje cell density, and immune infiltration in the cerebellum. We observed the production of anti-Yo antibodies in the CSF and serum of all immunized mice. Brain immunoreaction varied depending on the site of implantation of the tumor, with subcutaneous administration leading to a massive infiltration of immune cells in the meningeal spaces, choroid plexus, and cerebellar parenchyma. However, we did not observe massive Purkinje cell death nor any motor impairments in any of the experimental groups. Self-sustained neuro-inflammation might require a longer time to build up in our model. Unusual tumor antigen presentation and/or intrinsic, species-specific factors required for pro-inflammatory engagement in the brain may also constitute strong limitations to achieve massive recruitment of antigen-specific T-cells and killing of antigen-expressing neurons in this mouse model.

Keywords: Anti-Yo autoantibodies; Autoantibodies; CDR2L protein; Immune checkpoint inhibitors; Paraneoplastic cerebellar degeneration.

MeSH terms

  • Animals
  • Autoantibodies
  • Cerebellar Ataxia* / pathology
  • Cerebellum / pathology
  • Female
  • Humans
  • Mice
  • Paraneoplastic Cerebellar Degeneration*
  • Pilot Projects
  • Purkinje Cells / metabolism

Substances

  • Autoantibodies